Values First Advisors Inc. Raises Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Values First Advisors Inc. grew its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 277.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,970 shares of the biotechnology company's stock after purchasing an additional 3,655 shares during the quarter. Values First Advisors Inc.'s holdings in Blueprint Medicines were worth $433,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of the company. Quarry LP bought a new position in Blueprint Medicines during the third quarter valued at $32,000. R Squared Ltd bought a new position in Blueprint Medicines during the fourth quarter valued at $51,000. Covestor Ltd raised its stake in shares of Blueprint Medicines by 206.7% in the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company's stock valued at $55,000 after acquiring an additional 403 shares during the period. Quantbot Technologies LP purchased a new stake in shares of Blueprint Medicines in the third quarter valued at $108,000. Finally, CWM LLC lifted its holdings in shares of Blueprint Medicines by 69.2% in the 3rd quarter. CWM LLC now owns 1,870 shares of the biotechnology company's stock worth $173,000 after acquiring an additional 765 shares during the last quarter.

Wall Street Analyst Weigh In

BPMC has been the subject of a number of recent analyst reports. UBS Group assumed coverage on shares of Blueprint Medicines in a research note on Thursday, October 24th. They set a "neutral" rating and a $88.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and set a $135.00 target price on shares of Blueprint Medicines in a research note on Friday. Stephens reaffirmed an "overweight" rating and set a $140.00 target price on shares of Blueprint Medicines in a research note on Thursday, January 2nd. Piper Sandler upped their target price on Blueprint Medicines from $109.00 to $119.00 and gave the company a "neutral" rating in a research note on Monday, January 27th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $125.00 target price on shares of Blueprint Medicines in a research note on Friday. Two research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $123.83.

Blueprint Medicines Price Performance

Blueprint Medicines stock traded down $1.25 during mid-day trading on Friday, reaching $93.94. 1,260,678 shares of the company were exchanged, compared to its average volume of 950,529. The business has a fifty day moving average of $99.61 and a 200 day moving average of $94.57. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. Blueprint Medicines Co. has a 12-month low of $77.57 and a 12-month high of $121.90.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. As a group, research analysts forecast that Blueprint Medicines Co. will post -3.63 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Jeffrey W. Albers sold 15,161 shares of the company's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total value of $1,660,584.33. Following the transaction, the director now directly owns 152,396 shares of the company's stock, valued at $16,691,933.88. This represents a 9.05 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ariel Hurley sold 1,819 shares of the company's stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $93.26, for a total value of $169,639.94. Following the completion of the transaction, the insider now directly owns 14,967 shares in the company, valued at approximately $1,395,822.42. The trade was a 10.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 49,851 shares of company stock worth $4,984,696 over the last 90 days. Company insiders own 4.21% of the company's stock.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.